The short version
4 companies supply this market — a reasonable cushion if one runs into trouble. The price is down 15% over the past year, to $491.55 per unit.
Market view
infliximab-dyyb
25 marketed package NDCs · 4 active manufacturers
Most dispensed: INFLIXIMAB 100 mg/10mL · Injection, Powder, Lyophilized, For Solution · #1 vial, single-use/carton / 10 ml in 1 vial, single-use · Kit · #1 kit/carton / 1 kit in 1 kit * 1 syringe in 1 tray / 1 ml in 1 syringe * 1 ml in 1 packet · Kit · #2 kits/carton / 1 kit in 1 kit * 1 syringe in 1 tray / 1 ml in 1 syringe * 1 ml in 1 packet · Kit · #4 kits/carton / 1 kit in 1 kit * 1 syringe in 1 tray / 1 ml in 1 syringe * 1 ml in 1 packet
Price range and competition
RSS: changes for this drugEvery company selling this drug reports its own price. The line follows the middle of the pack; the shaded band holds the middle half of companies — the wider it is, the more they disagree.
Latest · Sep 2025 — typical price $491.55 · middle half $491.55–$491.55 · full range $491.55–$491.55 · 1 products · 4 companies
ⓘ How this was built
Data sources
- CMS NADAC weekly survey + monthly archives back to 2013 (data.medicaid.gov)
- CMS Federal Upper Limit files (weighted AMP)
- FDA NDC Directory (openFDA) — maker roster
Method
Each month's band spans the NADAC unit prices of every NDC of this drug (min, quartiles, median, max), split into brand and generic cohorts by FDA marketing category. Maker counts come from distinct labelers with the NDC actively listed.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
What changed in the last 90 days
Every detected change for infliximab-dyyb, newest first — price moves, shortages, recalls, and manufacturers entering or leaving. Detected by comparing each day’s federal data against the day before.
- ZymfentraAug 12, 2026Mfr exitedCELLTRION USA Inc. · infliximab-dyyb
Same drug class
Other molecules FDA puts in Tumor Necrosis Factor Blocker, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Infliximab-dyyb in shortage right now?
- No. FDA does not currently list Infliximab-dyyb in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Infliximab-dyyb?
- 4 companies have marketed Infliximab-dyyb in the last 30 days, according to the FDA NDC Directory. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.